
Overview
This review weighs transposon systems, mRNA and nanocarriers against viral vectors for making CAR T cells, and finds the non-viral route cheaper and more flexible. The review also reports that two of ten patients in a piggyBac trial developed malignant CAR T cell tumors.
What this paper found
Non-viral gene transfer with Sleeping Beauty (SB) and piggyBac (PB) transposons, mRNA and nanocarriers is positioned as a cheaper, more flexible route to CAR T cell manufacturing than viral vectors. Transposon plasmids are estimated to cost 5 to 10 times less than the viral process, and SB integrates in a close-to-random pattern, whereas PB prefers sites near transcription start sites. A multicenter phase I/II trial (NCT03389035) treated 21 patients with B-ALL relapsed after allogeneic transplant using SB-engineered CARCIK-CD19 cells; acute GvHD was never observed. In the PB-based CARTELL study, two of 10 treated patients developed malignant CAR T cell tumors, so the authors recommend limiting transposase activity and integration number and monitoring clonality.
Note: The authors note that whether transposon-engineered CAR T cells show unexpected toxicities and comparable clinical outcomes remains to be seen in additional clinical studies.
We are encouraged by the prospect of non-viral vectors simplifying the CAR T supply chain, making it less expensive, safer, and efficacious. — Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara F. Magnani, Frontiers in Immunology
Study details
- Authors
- Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara F. Magnani
- Institution
- Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca/Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Italy · CoImmune Inc., Durham, NC, United States · Department of Pediatrics, University of Milano - Bicocca, Milan, Italy · Clinica Pediatrica, University of Milano - Bicocca/Fondazione MBBM, Monza, Italy · Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
- Journal
- Frontiers in Immunology
- Year
- 2022
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy · Solid tumor
Explore related
Full citation
Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The Past, Present, and Future of Non-Viral CAR T Cells. Front Immunol. 2022;13:867013.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.